IVIG Therapy for CNS/ Neuromusc Dis: 55.2% of denials overturned
In 134 California IMR decisions from 2002 to 2025, reviewers overturned 74 (55.2%). In the last five years: 62.0% of 50. 90 were medical-necessity disputes, 44 experimental/investigational.
By year (last five)
| Year | Decisions | Overturned |
|---|---|---|
| 2021 | 12 | 75.0% |
| 2022 | 12 | 58.3% |
| 2023 | 4 | 75.0% |
| 2024 | 9 | 44.4% |
| 2025 | 13 | 61.5% |
What the findings mention
| What the findings mention | Decisions | Overturned | All decisions here |
|---|---|---|---|
| Published evidence citedThe findings refer to peer-reviewed or published evidence. | 54 | 63.0% | 55.2% |
| Prior therapies failedThe findings mention treatments that were tried without adequate response. | 24 | 75.0% | 55.2% |
| Step therapy or fail-firstThe findings mention a fail-first requirement. | 22 | 77.3% | 55.2% |
| Records did not supportThe findings say the documentation did not show what was needed (usually an upheld denial). | 16 | 12.5% | 55.2% |
| Guidelines or criteria citedThe findings cite guidelines, criteria or a standard of care. | 10 | 30.0% | 55.2% |
| Alternatives contraindicatedThe findings mention a contraindication to the plan's preferred option. | 7 | 57.1% | 55.2% |
| FDA approval or off-label use discussedThe findings discuss the FDA label status of the treatment. | 4 | 25.0% | 55.2% |
| Experimental or investigationalThe findings discuss whether the treatment is experimental. | 4 | 50.0% | 55.2% |
Keyword matches on the reviewer’s findings, not causes. A tag that appears mostly in overturned decisions is worth documenting in an appeal; it is not a guarantee.
From recent overturned decisions
“The physician reviewer found that a patient has requested authorization and coverage for intravenous immunoglobulin therapy with Octagam. Clinical documentation reflects a diagnosis of inflammatory muscle disease supported by electrodiagnostic and imaging findings. These findings are consistent with an inflammatory myopathy for which IVIG is an accepted therapeutic option. Therefore, the requested intravenous immunoglobulin therapy with Octagam is medically necessary …”
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: The patient’s parent has requested reimbursement and prospective authorization and coverage for Gammagard intravenous immunoglobulin (IVIG) therapy. As reported in the medical literature, treatment of intractable epilepsy specifically related to alternative hemiplegia of childhood is based on anecdotal reports, small observational studies, and expert opinion. As such, individual factors must …”
“Nature of Statutory Criteria/Case Summary: The patient has requested authorization and coverage for Ultomiris infusions. Ultomiris is a safe, U.S Food and Drug Administration (FDA)-approved treatment for neuromyelitis optica (NMO). The patient in this case has been diagnosed with NMO. The patient presents with symptoms of numbness, weakness, burning pain, shooting pain, lower extremity cramping, lower extremity spastic sensation, and …”
And one the reviewer upheld
“The physician reviewer found that Nature of Statutory Criteria/Case Summary: A patient has requested authorization and coverage for Gammaplex intravenous injection. An electromyography (EMG) consistent with a diagnosis of multifocal motor neuropathy typically demonstrates asymmetric motor neuropathy, accompanied by a characteristic conduction block. Per the medical records, the patient is being evaluated for proximal left arm weakness due to concern …”
- California only: these are decisions by independent reviewers under California's IMR program (plans regulated by the Department of Managed Health Care). Other states and self-funded employer plans use different reviewers and rules.
- Selection: only denials that a member took all the way to IMR appear. Most denials are never appealed, and the ones that reach an external reviewer are not a random sample.
- Overturned means the reviewer disagreed with the plan; it does not mean the treatment worked or that a similar request will be approved.
- Argument tags are keyword matches on the reviewer's findings. They describe what the findings mention, not why the case was decided.
- Categories are DMHC's own labels (treatment sub-category and diagnosis category); 'Other' is a catch-all and is excluded from rankings.
Source: California Department of Managed Health Care, Independent Medical Review (IMR) Determinations, Trend (CHHS Open Data). Public California government data; Apellica's aggregates and tags are CC BY 4.0.
Questions
How often were IVIG Therapy denials for CNS/ Neuromusc Dis overturned?
In 134 California IMR decisions from 2002 to 2025, reviewers overturned 74 (55.2%). In the last five years: 62.0% of 50. 90 were medical-necessity disputes, 44 experimental/investigational.
What should an appeal document, based on these findings?
Whatever the plan's criteria ask for, shown in the record: the treatments already tried and their results, contraindications to the plan's preferred option, the guideline or evidence that supports the request, and the treating clinician's reasoning written to the criteria. The tag table shows which of these the reviewers mentioned most in overturned cases.
Does a California IMR result apply to my plan?
Only California plans regulated by the Department of Managed Health Care go to IMR. Other states and self-funded employer plans use different reviewers, but they weigh the same things.
Independent reviewers reverse plans when the record answers the criteria. Upload the denial letter; a senior reviewer reads it within 24 hours and tells you in writing whether it can be appealed and how. $0 upfront, 10% of what is recovered, nothing if we do not recover. Not a law firm.